Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Agenus Inc
(NQ:
AGEN
)
7.420
+0.960 (+14.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agenus Inc
< Previous
1
2
3
Next >
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Today 10:00 EDT
From
Agenus Inc.
Via
Business Wire
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
April 23, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
April 12, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Reverse Stock Split of Common Stock
April 05, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
March 06, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
February 29, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in Leerink Partners Global Biopharma Conference
February 26, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024
From
Agenus Inc.
Via
Business Wire
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
January 22, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in B. Riley Healthcare Conference
January 04, 2024
From
Agenus Inc.
Via
Business Wire
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
December 20, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
December 11, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Reports Third Quarter 2023 Results
November 07, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
October 26, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
October 22, 2023
From
Agenus Inc.
Via
Business Wire
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
October 21, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
October 10, 2023
From
Agenus Inc.
Via
Business Wire
Agenus To Host BOT/BAL Program Update at ESMO 2023
October 05, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in September Investor Conferences
August 28, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
August 23, 2023
From
Agenus Inc.
Via
Business Wire
SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant
August 09, 2023
From
SaponiQx
Via
Business Wire
Agenus Reports Second Quarter 2023 Results
August 08, 2023
From
Agenus Inc.
Via
Business Wire
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
July 28, 2023
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
July 26, 2023
From
Agenus
Via
Business Wire
Agenus Expands Executive Leadership Team
July 20, 2023
From
Agenus Inc.
Via
Business Wire
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
June 30, 2023
From
Agenus
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.